Atrial Fibrillation - Pipeline Review, H2 2020

August 2020 | 134 pages | ID: AD7F669709AEN
Global Markets Direct

Abstracts

Atrial Fibrillation - Pipeline Review, H2 2020

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Atrial Fibrillation - Pipeline Review, H2 2020, provides an overview of the Atrial Fibrillation (Cardiovascular) pipeline landscape.

Atrial fibrillation is an irregular and often rapid heart rate that commonly causes poor blood flow to the body. Symptoms include decreased blood pressure, weakness, lightheadedness, confusion and chest pain. The predisposing factors include age, heart disease, high blood pressure, family history and drinking alcohol. Treatments for atrial fibrillation may include medications and surgery.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Atrial Fibrillation - Pipeline Review, H2 2020, provides comprehensive information on the therapeutics under development for Atrial Fibrillation (Cardiovascular), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Atrial Fibrillation (Cardiovascular) pipeline guide also reviews of key players involved in therapeutic development for Atrial Fibrillation and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 3, 8, 6, 1, 11, 1 and 1 respectively. Similarly, the Universities portfolio in Discovery stages comprises 1 molecules, respectively.

Atrial Fibrillation (Cardiovascular) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

• The pipeline guide provides a snapshot of the global therapeutic landscape of Atrial Fibrillation (Cardiovascular).
• The pipeline guide reviews pipeline therapeutics for Atrial Fibrillation (Cardiovascular) by companies and universities/research institutes based on information derived from company and industry-specific sources.
• The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
• The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
• The pipeline guide reviews key companies involved in Atrial Fibrillation (Cardiovascular) therapeutics and enlists all their major and minor projects.
• The pipeline guide evaluates Atrial Fibrillation (Cardiovascular) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
• The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
• The pipeline guide reviews latest news related to pipeline therapeutics for Atrial Fibrillation (Cardiovascular)

Reasons to Buy

• Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
• Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
• Find and recognize significant and varied types of therapeutics under development for Atrial Fibrillation (Cardiovascular).
• Classify potential new clients or partners in the target demographic.
• Develop tactical initiatives by understanding the focus areas of leading companies.
• Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
• Formulate corrective measures for pipeline projects by understanding Atrial Fibrillation (Cardiovascular) pipeline depth and focus of Indication therapeutics.
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
• Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Contents

Introduction
Atrial Fibrillation - Overview
Atrial Fibrillation - Therapeutics Development
Atrial Fibrillation - Therapeutics Assessment
Atrial Fibrillation - Companies Involved in Therapeutics Development
Atrial Fibrillation - Drug Profiles
Atrial Fibrillation - Dormant Projects
Atrial Fibrillation - Discontinued Products
Atrial Fibrillation - Product Development Milestones
Appendix

List Of Tables

LIST OF TABLES

Number of Products under Development for Atrial Fibrillation, H2 2020
Number of Products under Development by Companies, H2 2020
Number of Products under Development by Companies, H2 2020 (Contd..1), H2 2020
Number of Products under Development by Universities/Institutes, H2 2020
Products under Development by Companies, H2 2020
Products under Development by Companies, H2 2020 (Contd..1), H2 2020
Products under Development by Universities/Institutes, H2 2020
Number of Products by Stage and Target, H2 2020
Number of Products by Stage and Mechanism of Action, H2 2020
Number of Products by Stage and Route of Administration, H2 2020
Number of Products by Stage and Molecule Type, H2 2020
Atrial Fibrillation - Pipeline by Acesion Pharma Aps, H2 2020
Atrial Fibrillation - Pipeline by Allergan Ltd, H2 2020
Atrial Fibrillation - Pipeline by Allosteros Therapeutics Inc, H2 2020
Atrial Fibrillation - Pipeline by AnaBios Corp, H2 2020
Atrial Fibrillation - Pipeline by ARCA biopharma Inc, H2 2020
Atrial Fibrillation - Pipeline by Armaron Bio Pty Ltd, H2 2020
Atrial Fibrillation - Pipeline by Bayer AG, H2 2020
Atrial Fibrillation - Dormant Projects, H2 2020
Atrial Fibrillation - Dormant Projects, H2 2020 (Contd..1), H2 2020
Atrial Fibrillation - Dormant Projects, H2 2020 (Contd..2), H2 2020
Atrial Fibrillation - Discontinued Products, H2 2020
Atrial Fibrillation - Discontinued Products, H2 2020 (Contd..1), H2 2020

List Of Figures

LIST OF FIGURES

Number of Products under Development for Atrial Fibrillation, H2 2020
Number of Products under Development by Companies, H2 2020
Number of Products by Top 10 Targets, H2 2020
Number of Products by Stage and Top 10 Targets, H2 2020
Number of Products by Top 10 Mechanism of Actions, H2 2020
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2020
Number of Products by Routes of Administration, H2 2020
Number of Products by Stage and Routes of Administration, H2 2020
Number of Products by Molecule Types, H2 2020
Number of Products by Stage and Molecule Types, H2 2020

COMPANIES MENTIONED

Acesion Pharma Aps
Allergan Ltd
Allosteros Therapeutics Inc
AnaBios Corp
ARCA biopharma Inc
Armaron Bio Pty Ltd
Bayer AG
Chaperone Pharma BV
Chong Kun Dang Pharmaceutical Corp
Correvio Pharma Corp
Daiichi Sankyo Co Ltd
Espero BioPharma Inc
FB HRS LLC
G3 Pharmaceuticals Inc
HUYA Bioscience International LLC
Hyloris Pharmaceuticals SA
InCarda Therapeutics Inc
Merck & Co Inc
Merz Pharma GmbH & Co KgaA
Milestone Pharmaceuticals Inc
MyoKardia Inc
Nissan Chemical Corp
Novartis AG
OMEICOS Therapeutics GmbH
Rhythm Therapeutics Inc
Rithim Biologics Inc
The Geneva Biotech Center SA
Toa Eiyo Ltd
Verseon Corp
Vivasc Therapeutics Inc